Sai Life Expands Bidar API Capacity to 700 KL
ECONOMY & POLICY

Sai Life Expands Bidar API Capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO) focused on pharmaceutical innovation, has announced the completion of Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka.
Phase I of PB-11, inaugurated in December 2024, added 110 kilolitres (KL) of capacity. With the addition of approximately 91 KL in Phase II during Q1 FY26, PB-11 now totals nearly 200 KL of reactor volume—making it the single largest production block at the site. This expansion increases Sai Life’s total installed reactor capacity at the Bidar facility to around 700 KL.

Commenting on the development, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, stated, “This expansion is not just about capacity—it’s about scalability, reliability, and the ability to support clients as their needs evolve. We are enabling faster, more secure drug development by strengthening our commercial-scale API and intermediate manufacturing.”

PB-11 is a versatile block designed for the large-scale production of commercial products. Unit IV in Bidar serves as Sai Life’s core manufacturing hub, catering to highly regulated markets including the US, EU, and Japan.

Key features of the facility include:
  • 12 multipurpose production blocks totalling ~700 KL
  • Dedicated units for high-potency APIs (HPAPIs)
  • Advanced QC laboratories ensuring regulatory compliance
  • Capabilities such as lyophilisation, cryogenic and high-pressure reactions, and large-scale chromatography
The site has passed inspections by global regulatory bodies including the USFDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life’s manufacturing units had completed over 75 customer audits in the past three years—underscoring the company’s commitment to safety, quality, and regulatory excellence. 

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO) focused on pharmaceutical innovation, has announced the completion of Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka.Phase I of PB-11, inaugurated in December 2024, added 110 kilolitres (KL) of capacity. With the addition of approximately 91 KL in Phase II during Q1 FY26, PB-11 now totals nearly 200 KL of reactor volume—making it the single largest production block at the site. This expansion increases Sai Life’s total installed reactor capacity at the Bidar facility to around 700 KL.Commenting on the development, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, stated, “This expansion is not just about capacity—it’s about scalability, reliability, and the ability to support clients as their needs evolve. We are enabling faster, more secure drug development by strengthening our commercial-scale API and intermediate manufacturing.”PB-11 is a versatile block designed for the large-scale production of commercial products. Unit IV in Bidar serves as Sai Life’s core manufacturing hub, catering to highly regulated markets including the US, EU, and Japan.Key features of the facility include:12 multipurpose production blocks totalling ~700 KLDedicated units for high-potency APIs (HPAPIs)Advanced QC laboratories ensuring regulatory complianceCapabilities such as lyophilisation, cryogenic and high-pressure reactions, and large-scale chromatographyThe site has passed inspections by global regulatory bodies including the USFDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life’s manufacturing units had completed over 75 customer audits in the past three years—underscoring the company’s commitment to safety, quality, and regulatory excellence. 

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code